Post-refractive IOL Outcomes With Clareon TruPlus

Recruiting now

Conditions studied: Cataract

In brief

This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.

Key facts

Study ID

NCT07610226

Run by

Laser Defined Vision

People needed

35

Starts

2026-06-25

Expected to finish

2027-06-23

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to understand and sign informed consent.
• Adult patients (>45 years old) undergoing age-related cataract surgery that previously had myopic corneal refractive surgery.
• Dominant eye targeted for emmetropia, non-dominant eye may be targeted for ≤-0.75D (mini-monovision).
• Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes pre-operatively as determined by surgeon.
• Normal ocular findings aside from cataract.

You may not qualify if…

• Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation.
• Previous history of any ocular surgery, except for myopic LASIK or PRK.
• Previous hyperopic refractive surgery.
• Corneal HOA ≥1.0 µm (RMS) with OPD at 4mm scan.
• Any active ocular infection or inflammation.

Where it is running

• Physicians Protocol — Greensboro, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.